81
52
Growth Score
-3 pts
Heat Score
9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
274249
Noramco design, construct and manage a bulk active pharmaceutical ingredient plant in Wilmington.
- Alan Majewski: President & CFO
- Lee Karras: Group Chief ExecutivePast Role: IBA Molecular, President - North America
Johnson & Johnson
About the Company
Noramco was formed in 1979 to design, construct and manage a bulk active pharmaceutical ingredient plant in Wilmington, Delaware to support Ortho-McNeil Pharmaceutical's Tylenol® with codeine business. With the acquisition of Tasmanian Alkaloids and addition of the Athens, Georgia site in 1982, and continuous expansions over the past three
decades at both US facilities, Noramco now contributes to billion dollar affiliate franchises, as well as to significant 3rd party generic and branded pharmaceutical products worldwide.
